Who are Triumvira Immunologics's investors?

Triumvira Immunologics's investors include B Capital Group, B4 Capital, Checkmate Capital Group LLC.

How much funding has Triumvira Immunologics raised?

Triumvira Immunologics has disclosed $59.7M raised across 1 round.

Where is Triumvira Immunologics headquartered?

Triumvira Immunologics is headquartered in Austin, US.

Triumvira Immunologics

Austin, US · Founded 2015 · Ontario, Canada corporation · 21 employees on LinkedIn · 3 known investors

Triumvira develops TAC (T cell Antigen Coupler) technology that enables T cells to target and destroy tumor cells, applicable across liquid and solid cancers. The company is building a pipeline of TAC-T cell therapies using both autologous and allogeneic manufacturing approaches for cancers with high unmet need.

Biotech Healthtech

Founders & leadership

TERESA MCROBERTSExecutive

PAUL LAMMERS, MD, MScExecutive

JON IRVINExecutive

Board

DANIEL JANSEBoard director

JURGEN ECKHARDTBoard director

ELIZABETH WILLIAMSBoard director

WIDYA MULYASASMITA in 𝕏Board of Directors2022–2023Principal at B Capital Group

BRIAN M. BLOOMBoard director

LEE COOPERBoard director

CYNTHIA COLLINS, MBABoard director

SCOTT SMITHBoard director

Investors · 3

B Capital GroupManhattan Beach · $10M – $50M

B4 Capital$10M – $50M

Checkmate Capital Group LLCPasadena

Reported raises · per SEC filings

Form D private placements

$59.7M disclosed across 1 round · 2021

▶$59.7MraisedSep 2022 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

CYNTHIA COLLINS, MBADirector
SCOTT SMITHDirector
DANIEL JANSEDirector
JURGEN ECKHARDTDirector
TERESA MCROBERTSExecutive Officer
PAUL LAMMERS, MD, MScExecutive Officer, Director
ELIZABETH WILLIAMSDirector
JON IRVINExecutive Officer
WIDYA MULYASASMITADirector
BRIAN M. BLOOMDirector
LEE COOPERDirector

Offering amount: $59.7M
Amount sold: $59.7M
First sale: Apr 2021
Incorporated: Corporation, Ontario, Canada
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Triumvira Immunologics do?: Triumvira develops TAC (T cell Antigen Coupler) technology that enables T cells to target and destroy tumor cells, applicable across liquid and solid cancers. The company is building a pipeline of TAC-T cell therapies using both autologous and allogeneic manufacturing approaches for cancers with high unmet need.
Who are Triumvira Immunologics's investors?: Triumvira Immunologics's investors include B Capital Group, B4 Capital, Checkmate Capital Group LLC.
How much funding has Triumvira Immunologics raised?: Triumvira Immunologics has disclosed $59.7M raised across 1 round.
Where is Triumvira Immunologics headquartered?: Triumvira Immunologics is headquartered in Austin, US.